(Q28196720)

2

0 references

Masami Nishino

3

0 references

Jun Tanouchi

4

0 references

Kinya Otsu

5

0 references

Masatsugu Hori

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

6

0 references

language of work or name

English

0 references

publication date

July 2003

0 references

published in

Atherosclerosis

0 references

volume

169

0 references

issue

1

0 references

page(s)

155-8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

The pathogenesis of atherosclerosis: a perspective for the 1990s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Molecular bases of the acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Immunoglobulins and complement components in human aortic atherosclerotic intima

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Direct proinflammatory effect of C-reactive protein on human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Aspirin, heparin, or both to treat acute unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8

Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2803%2900158-8